- Home
- ZYME vs MYGN Comparison
ZYME vs MYGN Comparison
Compare ZYME & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- MYGN
- Stock Information
- Founded
- ZYME 2003
- MYGN 1991
- Country
- ZYME United States
- MYGN United States
- Employees
- ZYME N/A
- MYGN N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ZYME Health Care
- MYGN Health Care
- Exchange
- ZYME Nasdaq
- MYGN Nasdaq
- Market Cap
- ZYME 846.1M
- MYGN 744.7M
- IPO Year
- ZYME 2017
- MYGN 1995
- Fundamental
- Price
- ZYME $11.43
- MYGN $4.19
- Analyst Decision
- ZYME Buy
- MYGN Hold
- Analyst Count
- ZYME 7
- MYGN 16
- Target Price
- ZYME $19.50
- MYGN $15.47
- AVG Volume (30 Days)
- ZYME 449.0K
- MYGN 3.3M
- Earning Date
- ZYME 05-08-2025
- MYGN 05-06-2025
- Dividend Yield
- ZYME N/A
- MYGN N/A
- EPS Growth
- ZYME N/A
- MYGN N/A
- EPS
- ZYME N/A
- MYGN N/A
- Revenue
- ZYME $93,384,000.00
- MYGN $831,300,000.00
- Revenue This Year
- ZYME $34.23
- MYGN N/A
- Revenue Next Year
- ZYME $68.78
- MYGN $6.42
- P/E Ratio
- ZYME N/A
- MYGN N/A
- Revenue Growth
- ZYME 85.05
- MYGN 7.38
- 52 Week Low
- ZYME $8.21
- MYGN $3.81
- 52 Week High
- ZYME $17.70
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- ZYME 45.92
- MYGN 33.61
- Support Level
- ZYME $11.46
- MYGN $3.86
- Resistance Level
- ZYME $11.81
- MYGN $4.38
- Average True Range (ATR)
- ZYME 0.59
- MYGN 0.26
- MACD
- ZYME -0.05
- MYGN 0.14
- Stochastic Oscillator
- ZYME 27.62
- MYGN 54.29
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.